3 Pathology Lab Chain, Surfactant Supplier and Riding Gear Stocks With a Strong Future Roadmap: Suraksha Diagnostic, Galaxy Surfactants and Studds Accessories

Pathology lab chain, surfactant supplier and riding gear stocks give investors exposure to health tests, personal care inputs and riding safety. Volumes, pricing and margins decide how much of that demand turns into profit.

This list covers three pathology lab chain, surfactant supplier and riding gear stocks: Suraksha Diagnostic for diagnostic and pathology testing through a network of labs and collection centres, Galaxy Surfactants for surfactants and specialty ingredients for personal care and home care brands and Studds Accessories for motorcycle helmets and riding accessories sold in India and overseas. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Pathology Lab Chain, Surfactant Supplier and Riding Gear Stocks?

Pathology lab chain, surfactant supplier and riding gear stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.

Pathology Lab Chain, Surfactant Supplier and Riding Gear Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three pathology lab chain, surfactant supplier and riding gear stocks as of the 14 Oct 2026 close.

Among healthcare, chemicals and consumer stocks, all three trade at a discount to their industry P/E multiples.

Why Do Pathology Lab Chain, Surfactant Supplier and Riding Gear Stocks Have a Strong Roadmap in India?

Pathology lab chain, surfactant supplier and riding gear stocks have a strong roadmap in India because diagnostic testing, personal care demand and two-wheeler ownership keep adding volumes for these firms. Three drivers stand out.

• Health testing: Families book more pathology and scan tests.
• Personal care: Brands buy surfactants and specialty ingredients.
• Two-wheeler riders: Safety rules lift helmet demand.

Suraksha Diagnostic: Diagnostic Labs Drive the Pipeline

Suraksha Diagnostic's roadmap rests on diagnostic and pathology testing through a network of labs and collection centres, with rising health screening supporting test volumes.

Revenue grew from Rs 225.50 crore in FY22 to Rs 313.58 crore in FY26, a 39.1% rise, and FY26 revenue was 22.5% higher than FY25. FY26 net profit rose 1.4% to Rs 31.40 crore. Over four years, net profit rose from Rs 23.75 crore in FY22 to Rs 31.40 crore. In Q1 FY27, revenue grew 20.7% to Rs 88.74 crore, and net profit rose 40.0% to Rs 12.85 crore. Operating margin was 32.01% in FY26 and 35.97% in Q1 FY27 against 33.97% a year earlier.

Debt to equity is 0.53 and return on equity is 13.15%. FY26 operating cash flow was Rs 81.83 crore against capital expenditure of Rs 67.34 crore. Suraksha Diagnostic paid a dividend of Rs 0.05 per share for FY26, a yield of 0.02%. At a P/E of 46.05 against an industry P/E of 62.79, the stock trades below its industry multiple.

What to watch: Q1 FY27 operating margin was 35.97% against 32.01% for FY26, so margin stability is the figure to follow as volumes grow.

Galaxy Surfactants: Personal Care Ingredients Anchor the Roadmap

Galaxy Surfactants' roadmap rests on surfactants and specialty ingredients for personal care and home care brands, with global consumer companies as customers supporting volumes.

Revenue grew from Rs 3,698.22 crore in FY22 to Rs 5,279.92 crore in FY26, a 42.8% rise, and FY26 revenue was 24.2% higher than FY25. FY26 net profit was Rs 267.38 crore. In Q1 FY27, revenue grew 38.5% to Rs 1,785.18 crore. Operating margin was 9.25% in FY26 and 14.17% in Q1 FY27 against 10.57% a year earlier.

Debt to equity is 0.09 and return on equity is 9.74%. FY26 operating cash flow was Rs 332.66 crore against capital expenditure of Rs 136.95 crore. Galaxy Surfactants paid a dividend of Rs 22 per share for FY26, a yield of 0.91%. At a P/E of 24.09 against an industry P/E of 36.60, the stock trades below its industry multiple.

What to watch: Q1 FY27 operating margin was 14.17% against 9.25% for FY26, so margin stability is the figure to follow as volumes grow.

Studds Accessories: Helmets and Riding Gear Build the Next Leg

Studds' roadmap rests on motorcycle helmets and riding accessories sold in India and overseas, with rising two-wheeler use and safety awareness supporting volumes.

Revenue grew from Rs 467.98 crore in FY22 to Rs 645.75 crore in FY26, a 38.0% rise, and FY26 revenue was 8.4% higher than FY25. FY26 net profit rose 18.7% to Rs 82.65 crore. Over four years, net profit rose from Rs 28.64 crore in FY22 to Rs 82.65 crore. In Q1 FY27, revenue grew 13.8% to Rs 172.92 crore. Operating margin was 21.25% in FY26.

Debt to equity is 0.02 and return on equity is 15.80%. FY26 operating cash flow was Rs 86.42 crore against capital expenditure of Rs 47.04 crore. Studds paid a dividend of Rs 3 per share for FY26, a yield of 0.72%. At a P/E of 21.92 against an industry P/E of 36.50, the stock trades below its industry multiple.

What to watch: The P/E of 21.92 against an industry P/E of 36.50 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Best Pathology Lab Chain, Surfactant Supplier and Riding Gear Stocks in India: Suraksha Diagnostic vs Galaxy Surfactants vs Studds on Key Financials

Among the best pathology lab chain, surfactant supplier and riding gear stocks in India, Suraksha Diagnostic leads on FY26 operating margin; Galaxy Surfactants leads on FY26 revenue growth and Q1 FY27 revenue growth; Studds leads on return on equity and the lowest P/E. The table puts the numbers side by side.

Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Pathology Lab Chain, Surfactant Supplier and Riding Gear Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen pathology lab chain, surfactant supplier and riding gear stocks and shortlist pathology lab chain, surfactant supplier and riding gear stocks to buy.

1. Compare each stock's P/E with its industry P/E, which differs by company here.
2. Check revenue growth, operating margin and cash flow together.
3. Check whether revenue growth is turning into profit growth, not only sales.
4. Read operating cash flow against capital expenditure to see how growth is funded.
5. Watch debt to equity and interest cover before sizing a position.
6. Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these pathology lab chain, surfactant supplier and riding gear stocks

Risks to Consider Before Investing in Pathology Lab Chain, Surfactant Supplier and Riding Gear Stocks

• Consumer demand: Spending patterns can shift sales between quarters.
• Input costs: Changes in raw material prices can affect margins.
• Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.

Download the Univest iOS App or Univest Android App to track Suraksha Diagnostic, Galaxy Surfactants and Studds live.

Final Take: Which Stock Has the Strongest Roadmap?

These three healthcare, chemicals and consumer stocks cover a diagnostic chain, a specialty chemical maker and a helmet brand. Suraksha Diagnostic leads on FY26 operating margin; Galaxy Surfactants leads on FY26 revenue growth and Q1 FY27 revenue growth; Studds leads on return on equity and the lowest P/E.

Across pathology lab chain, surfactant supplier and riding gear stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the pathology lab chain, surfactant supplier and riding gear stocks to buy discussed here.

FAQs on Pathology Lab Chain, Surfactant Supplier and Riding Gear Stocks

Which are the best pathology lab chain, surfactant supplier and riding gear stocks in India with a strong roadmap?

Ans. Suraksha Diagnostic, Galaxy Surfactants and Studds Accessories stand out for their roadmaps in a diagnostic chain, a specialty chemical maker and a helmet brand. FY26 revenue growth was 22.5% at Suraksha Diagnostic, 24.2% at Galaxy Surfactants and 8.4% at Studds, and return on equity ranges from 9.74% to 15.80%.

Is Suraksha Diagnostic a good stock to buy now?

Ans. Suraksha Diagnostic has a debt to equity ratio of 0.53, a return on equity of 13.15% and a P/E of 46.05 against an industry P/E of 62.79. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Suraksha Diagnostic, Galaxy Surfactants and Studds?

Ans. The P/E ratio is 46.05 for Suraksha Diagnostic (industry 62.79), 24.09 for Galaxy Surfactants (industry 36.60) and 21.92 for Studds (industry 36.50). All of them trade below the industry multiple.

Which of these pathology lab chain, surfactant supplier and riding gear stocks has the highest return on equity?

Ans. Studds Accessories has the highest return on equity at 15.80%, followed by Suraksha Diagnostic at 13.15% and Galaxy Surfactants at 9.74%.

What are the risks of investing in pathology lab chain, surfactant supplier and riding gear stocks?

Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.

How did Suraksha Diagnostic, Galaxy Surfactants and Studds perform in Q1 FY27?

Ans. Suraksha Diagnostic reported revenue of Rs 88.74 crore, up 20.7% year on year, and net profit rose 40.0% to Rs 12.85 crore. Galaxy Surfactants reported revenue of Rs 1,785.18 crore, up 38.5% year on year. Studds Accessories reported revenue of Rs 172.92 crore, up 13.8% year on year.

Do pathology lab chain, surfactant supplier and riding gear stocks pay dividends?

Ans. Yes, all three companies pay dividends. The dividend yield is 0.02% for Suraksha Diagnostic, 0.91% for Galaxy Surfactants and 0.72% for Studds, based on dividends declared for FY26.

How can I invest in pathology lab chain, surfactant supplier and riding gear stocks in India?

Ans. You can buy pathology lab chain, surfactant supplier and riding gear stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.